CA2367247A1 - Compositions et procedes d'utilisation de ligands recepteurs du type ldl pour le traitement du cancer et de maladies angiogeniques - Google Patents

Compositions et procedes d'utilisation de ligands recepteurs du type ldl pour le traitement du cancer et de maladies angiogeniques Download PDF

Info

Publication number
CA2367247A1
CA2367247A1 CA002367247A CA2367247A CA2367247A1 CA 2367247 A1 CA2367247 A1 CA 2367247A1 CA 002367247 A CA002367247 A CA 002367247A CA 2367247 A CA2367247 A CA 2367247A CA 2367247 A1 CA2367247 A1 CA 2367247A1
Authority
CA
Canada
Prior art keywords
inhibitor
protein
proteinase
low density
density lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002367247A
Other languages
English (en)
Inventor
Shawn J. Green
Adonia E. Papathanassiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2367247A1 publication Critical patent/CA2367247A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des procédés efficaces pour l'inhibition de la prolifération de cellules anormales ou indésirables, en particulier de cellules endothéliales et d'angiogénèse en rapport avec une néoformation de vaisseaux sanguins et un développement de tumeurs. Les compositions comprennent des protéines, peptides, ou fragments de protéines synthétiques ou se présentant à l'état naturel, capables de lier des récepteurs de lipoprotéine faible densité (ou du type lipoprotéine faible densité). Les compositions peuvent être administrées par l'intermédiaire d'un support pharmaceutiquement acceptable. Les procédés concernent l'administration des compositions précitées à un être humain ou à un animal, en un dosage suffisant pour inhiber la prolifération des cellules, en particulier, des cellules endothéliales. Ces procédés sont utilisés pour le traitement de maladies et de processus, tels que le cancer, à médiation par prolifération cellulaire non désirée et non contrôlée, en particulier par inhibition d'angiogénèse. L'administration des compositions de l'invention à un être humain ou à un animal présentant des tumeurs métastasées prévascularisées est utilisée pour prévenir la croissance ou l'expansion de telles tumeurs.
CA002367247A 1999-03-17 2000-03-17 Compositions et procedes d'utilisation de ligands recepteurs du type ldl pour le traitement du cancer et de maladies angiogeniques Abandoned CA2367247A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27098299A 1999-03-17 1999-03-17
US09/270,982 1999-03-17
PCT/US2000/007154 WO2000054801A1 (fr) 1999-03-17 2000-03-17 Compositions et procedes d'utilisation de ligands recepteurs du type ldl pour le traitement du cancer et de maladies angiogeniques

Publications (1)

Publication Number Publication Date
CA2367247A1 true CA2367247A1 (fr) 2000-09-21

Family

ID=23033688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002367247A Abandoned CA2367247A1 (fr) 1999-03-17 2000-03-17 Compositions et procedes d'utilisation de ligands recepteurs du type ldl pour le traitement du cancer et de maladies angiogeniques

Country Status (5)

Country Link
EP (1) EP1161258A1 (fr)
JP (1) JP2002539174A (fr)
AU (1) AU4449900A (fr)
CA (1) CA2367247A1 (fr)
WO (1) WO2000054801A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593291B1 (en) * 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
DE19937656A1 (de) * 1999-08-13 2001-02-15 Aventis Behring Gmbh Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
DE10102048A1 (de) * 2001-01-17 2002-07-18 Aventis Behring Gmbh Antithrombin III gegen durch Angiogenese verursachte Krankheiten
WO2003015615A2 (fr) 2001-08-15 2003-02-27 Brown University Research Foundation Traitement de dystrophies musculaires et de troubles connexes
CA2457008A1 (fr) 2001-08-20 2003-02-27 University Of Connecticut Health Center Procedes de preparation de compositions a base de proteines du stress ou de $g(a)-2- macroglobuline utilisees dans le traitement du cancer et des maladies infectieuses
US20030165485A1 (en) * 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
AU2003273176A1 (en) 2002-05-17 2003-12-12 Board Of Regents, The University Of Texas System Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
WO2004050125A1 (fr) * 2002-12-03 2004-06-17 Koken Co.,Ltd. Inhibiteur de proliferation et/ou d'infiltration de cellules tumorales
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP2571514B1 (fr) 2010-05-17 2018-07-18 Brown University Mutants de biglycanes et produits thérapeutiques associés et méthodes d'utilisation
EP3026432A3 (fr) 2010-12-27 2016-07-27 Brown University Procédé de prévision de la réponse du patient au traitement avec biglycan
CN102210721A (zh) * 2011-05-30 2011-10-12 大连海洋大学 米氏凯伦藻提取物、制备方法及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950702430A (ko) * 1992-08-12 1995-07-29 심파쓰 아포리포프로테인 이(Apolipoprotein E)를 이용한 세포증식 억제방법
US5650391A (en) * 1994-03-21 1997-07-22 Jewish Hospital Of St. Louis Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation

Also Published As

Publication number Publication date
EP1161258A1 (fr) 2001-12-12
JP2002539174A (ja) 2002-11-19
WO2000054801A1 (fr) 2000-09-21
AU4449900A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
US6593291B1 (en) Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US6734163B2 (en) Compositions and methods for inhibiting cellular proliferation
CA2367247A1 (fr) Compositions et procedes d'utilisation de ligands recepteurs du type ldl pour le traitement du cancer et de maladies angiogeniques
US20120189673A1 (en) Polypeptides and uses thereof
US20060142203A1 (en) Compositions and methods comprising protein activated receptor antagonists
AU2843900A (en) Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof
CN103068845A (zh) 用于治疗间质性肺病的因子xii抑制剂
BR112014004297B1 (pt) Uso de um inibidor de antitrombina iii no tratamento ou prevenção de sangramento
US7205392B2 (en) Histidine-rich glycoprotein
US5190919A (en) Antihemostatic factor vii peptides
Phan et al. Role of fibronectin and fibrinogen in healing of corneal epithelial scrape wounds.
Van De Craen et al. Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo
US7300916B2 (en) Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
US6946439B2 (en) Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US20060025329A1 (en) Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US20210189368A1 (en) Recombinant fusion proteins for preventing or treating adhesions of tissues or organs
JP2007528710A (ja) 内因性ペプチドおよびその活性サブフラグメント
AU2002304352A1 (en) Histidine-rich glycoprotein
HU225784B1 (en) Ancrod specific monoclonal antibodies, antibody fragments and mixtures thereof, pharmaceutical preparations containing them and use of the same

Legal Events

Date Code Title Description
FZDE Dead